Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 47 of the 72 sources its claims cite were checked for support.

Targeting TBK1 to overcome resistance to cancer immunotherapy

Open access

Abstract

Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking 1,2. Here we identify the innate immune kinase TANK-binding kinase 1 (TBK1)3 as a candidate immune-evasion gene in a pooled genetic screen 4. Using a suite of genetic and pharmacological tools across multiple experimental model systems, we confirm a role for TBK1 as an immune-evasion gene. Targeting TBK1 enhances responses to PD-1 blockade by decreasing the cytotoxicity threshold to effector cytokines (TNF and IFNγ). TBK1 inhibition in combination with PD-1 blockade also demonstrated efficacy using patient-derived tumour models, with concordant findings in matched patient-derived organotypic tumour spheroids and matched patient-derived organoids. Tumour cells lacking TBK1 are primed to undergo RIPK- and caspase-dependent cell death in response to TNF and IFNγ in a JAK-STAT-dependent manner. Taken together, our results demonstrate that targeting TBK1 is an effective strategy to overcome resistance to cancer immunotherapy.

Overview

CoChat Summary

TL;DR

TBK1 is identified as a tumour-intrinsic immune evasion kinase, and genetic or pharmacologic TBK1 inhibition sensitizes tumours to PD-1 blockade by lowering the threshold for TNFα/IFNγ-induced RIPK- and caspase-dependent cell death. In murine and patient-derived models, TBK1 inhibition plus PD-1 blockade improved tumour control, including in immunotherapy-resistant melanoma.

Key findings

  • In B16 melanoma, Tbk1 sgRNAs were depleted after PD-1 blockade; Tbk1-null tumours grew comparably to controls in immunodeficient NSG and wild-type mice but showed improved tumour shrinkage and survival with anti-PD-1. TBK1i plus anti-PD-1 improved tumour control in B16-ova, D4M.3A, acquired-resistant B16-ova MDOTS, MC38, and MB49 models.
  • In patient-derived organotypic tumour spheroids (PDOTS; n=30: cutaneous melanoma n=15, non-cutaneous melanoma n=2, other cancers n=13), response rates were 30% for TBK1i, 40% for TBK1i plus PD-1 blockade, and 16.6% for single-agent PD-1 blockade. Responses occurred in immunotherapy-resistant metastatic cutaneous melanoma and MSI colorectal carcinoma.
  • Single-cell RNA-seq of CD45+ cells (n=53,637) from B16-ova tumours showed TBK1i ± anti-PD-1 expanded myeloid cells, pro-inflammatory macrophages, and early exhausted/effector CD8+ T cells, while reducing terminal exhausted/effector CD8+ T cells and MDSCs; Tnf and Il1a were enhanced. Tbk1-null tumours showed limited immune remodeling by scRNA-seq (n=31,810 CD45+ cells).
  • Tbk1-null B16 cells were sensitive to combined TNFα/IFNγ but not either cytokine alone; death required RIPK and caspase signaling and intact IFNγ/JAK-STAT sensing, while STING and IRF3 were dispensable. TBK1i lowered the cytotoxic threshold to TNFα/IFNγ in A375 melanoma cells, PDOTS, and matched patient-derived organoids.

Methods

  • Pooled CRISPR-Cas9 screens were performed in vivo in B16 melanoma and in vitro in control and Tbk1-null B16 cells challenged with TNFα/IFNγ. Validation used syngeneic murine tumour models (B16, B16-ova, CT26, D4M.3A, MC38, MB49), murine-derived organotypic tumour spheroids (MDOTS), and pharmacologic TBK1 inhibitors.
  • Patient-derived PDOTS and PDOs from melanoma and other cancers were cultured ex vivo in 3D microfluidic devices or Matrigel with anti-PD-1, TBK1i, and/or cytokines; viability was assessed by fluorescence live/dead staining or CellTiter-Glo. Additional analyses included scRNA-seq of CD45+ tumour-infiltrating cells, Olink plasma proteomics in metastatic melanoma patients, growth rate inhibition metrics, immunoblotting, flow cytometry, and qRT-PCR.

Limitations

  • Stated: future studies are required to deconvolute the roles of TBK1 in distinct immune cell populations and to determine the therapeutic potential of disrupting TBK1 signaling in melanoma patients resistant to immunotherapy. The paper also states that murine models lack the heterogeneity of human cancer, while patient-derived models are heterogeneous and more complex.
  • Stated/evident: animal studies did not use statistical methods to predetermine sample size, used at least five mice per group, and no blinding was performed; TBK1i in vivo studies also state that investigators were not blinded to treatment groups.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41586-023-05704-6

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

27 Valid · 1 Not valid · 11 Not checked · 127 Own results and interpretations

77 more claims · 7 with their cited sources checked

Create a free account to see all 166 claims and to verify the 7 references still open.

See all claims — free account
  • Probably not a substantial claim. 41
  • It may state two separate claims as one. 52

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 73 references

Cited by

See all 174

Metadata

Authors
Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., Fu, A., Ma, X., Gwee, J., Tiwari, P., Du, P. P., Sindurakar, P., Tian, J., Mehta, A., Schneider, A. M., Yizhak, K., Sade-Feldman, M., LaSalle, T., Sharova, T., Xie, H., Liu, S., Michaud, W. A., Saad-Beretta, R., Yates, K. B., Iracheta-Vellve, A., Spetz, J. K. E., Qin, X., Sarosiek, K. A., Zhang, G., Kim, J. W., Su, M. Y., Cicerchia, A. M., Rasmussen, M. Q., Klempner, S. J., Juric, D., Pai, S. I., Miller, D. M., Giobbie-Hurder, A., Chen, J. H., Pelka, K., Frederick, D. T., Stinson, S., Ivanova, E., Aref, A. R., Paweletz, C. P., Barbie, D. A., Sen, D. R., Fisher, D. E., Corcoran, R. B., Hacohen, N., Sorger, P. K., Flaherty, K. T., Boland, G. M., Manguso, R. T., & Jenkins, R. W.
Affiliations
  • Harvard University (US)
  • Broad Institute (US)
  • Technion – Israel Institute of Technology (IL)
  • The Wistar Institute (US)
  • University of California San Diego (US)
  • Gilead Sciences (United States) (US)
  • Dana-Farber Cancer Institute (US)
Corresponding author
Jenkins, Russell W.
Venue
Nature
Published
2023-01-12
Volume
615
Issue
7950
Pages
158-167
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4315784559
Cited by
174
References
73
Citations by year
2026: 33 · 2025: 61 · 2024: 53 · 2023: 26
FWCI
21.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Melanoma Research Alliance (https://doi.org/10.48050/pc.gr.86371)
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • Deutsche Forschungsgemeinschaft
  • National Institutes of Health
  • Stand Up To Cancer
  • National Cancer Institute (K08CA226391, R01CA222871, K99CA259511, T32CA207021, P01CA240239, R37CA248565, P01CA163222)
  • National Institute of General Medical Sciences (T32GM007753)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125263)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR072304, R01AR043369)
  • National Institute of Dental and Craniofacial Research (U01DE033324)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
TBK1, cancer immunotherapy resistance, anti-PD-1 therapy, immune evasion, innate immune signaling, TNF-α, interferon-gamma, JAK/STAT signaling, caspase-dependent cell death, kinase inhibition
MeSH terms
Humans, Immunotherapy, Interferon-gamma, Organoids, Protein Serine-Threonine Kinases, Spheroids, Cellular, Drug Resistance, Neoplasm, Caspases, Tumor Necrosis Factors, STAT Transcription Factors, Janus Kinases, Immune Evasion, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting TBK1 to overcome resistance to cancer immunotherapy. https://app.cochat.ai/papers/10.1038/s41586-023-05704-6
The paper
Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., Fu, A., Ma, X., Gwee, J., Tiwari, P., Du, P. P., Sindurakar, P., Tian, J., Mehta, A., Schneider, A. M., . . . Jenkins, R. W. (2023). Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. https://doi.org/10.1038/s41586-023-05704-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.